Oncopeptides Q2 2025: Funded Until Profitability - Redeye

Redeye comments on Oncopeptides’ 2nd quarter report, which saw significant sales progress in the core German, Spanish, and Italian markets. Although still early in its rollout, there are now signs that Pepaxti may become a commercial success in Europe. The rights issue of SEK150m announced at the same time should cover operations through 2026 and until there is a positive cash flow.

Länk till analysen i sin helhet: https://www.redeye.se/research/1123872/oncopeptides-q2-2025-funded-until-profitability?utm_source=finwire&utm_medium=RSS